[amazon_link asins=’B01F1AHQNM,1501143727,B004YSDT52,0805089586,1626253439,1572246359,1456492543,B01LZHCDJU,B003ELMR9E’ template=’ProductCarousel’ store=’finmeacur-20′ marketplace=’US’ link_id=’a0d657e7-6063-11e7-81a4-5d4a58aefbbe’]
They found that blocking brain receptors for orexin, a blood peptide, promoted sleep in rats, dogs and people, according to a paper in Sunday’s online issue of the journal Nature Medicine.
Orexin, also known as hypocretin, is important in maintaining wakefulness. It is absent in the brains of people who suffer from narcolepsy, a chronic disorder in which people cannot regulate sleep-wake cycles normally.
They developed a drug that can block the receptors in the brain that respond to orexin-hypocretin. The researchers reported successful testing in rodents, dogs and men.
The first tests were proof of the concept and the drug is now being evaluated to establish the correct dosage, said Roland Haefeli, an Actelion spokesman.
Researchers hope to decide this year whether to conduct a phase-three study, a detailed assessment of the drug that would be the final step before seeking US government approval for its use. Such studies can take a few years.
Narcolepsy victims often also experience cataplexy, a condition in which they lose control of muscle tone for a few seconds to minutes. Jenck said in a telephone interview that the drug tests did not prompt indications of cataplexy.
“I think it may be the beginning of something quite exciting,” said Scammell, who was not part of the research team.
Source:The Times Of India